Skip to main content

Table 2 Disease burden and results of investigations in Severe Asthma Clinic patients

From: Clinical and lung function outcomes in a cohort of children with severe asthma

Severe Asthma Clinic children (n = 23)

Hospital Admissions in the previous year

10 (43)c

Number of Hospital admissions in the previous year

3/3(0.9/1–4)d

Number of children with Positive Skin Prick Test

19 (83)c

Number of children with serum Specific IgE positive

18 (78)c

Aspergillus

4 (22) c

D pteronys

15 (65) c

Australia treemix

4 (22) c

Cat epithelia

7 (30) c

Dog dander

9 (50) c

Weed mix

4 (22) c

Grass mix

7 (30) c

Mould mix

4 (22) c

Blood eosinophils levelsa

909/800 (66/0–2900) d

Serum Immunoglobulin E (IU/mL) a

1257/1210 (1125/165–4565)d

Age at symptoms onset in yearsa

3.7/1.5 (3.9/0.5–12) d

Age at visit date in years

11.4/12 (2.7/4–16) d

ICSb (mcg/day)

1851/2000 (642/640–4000) d

Number of children with ACT score ≤ 19

17 (74) c

ACT score

14.2/12 (5.4/8–25) d

Quality of Life Questionnaire score a

5.2/5.3 (1.1/3.1–7) d

ACQ-5a

1.8/1.8 (1/0–3.8)d

PI-ED

9(38)c

Anxiety

Depression

5/3 (6.6/0–20)

0.6/0 (1.3/0–3)

Number of children under treatment with Azithromycin

7 (30) c

Nasal steroids

16 (70)c

Bronchoscopy

9 (39c)

Bronchoalveolar Lavage Fluid (BALF)a

7 (30) c

% Macrophage

86.4/88 (12.6/68–99.5) d

% Eosinophil

2.8/1.3 (7.5/0.5–21) d

% Lymphocyte

7.9/7.5 (8.8/0.5–26) d

% Neutrophil

4.7/1 (8.0/0.5–19) d

  1. aBALF analysis n = 7; serum IgE n = 23; age at symptoms onset in years n = 15; blood eosinophils levels n = 21; Quality of Life questionnaire n = 13; ACQ-5 n = 14
  2. bICS Inhaled corticosteroid;cValues presented as n (% of total)
  3. dValues presented as Mean/median (SD/min-max)